Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Insider Robert Berman Sells 35,000 Shares

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $30.11, for a total transaction of $1,053,850.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Robert Berman also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, February 12th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.42, for a total transaction of $1,064,700.00.
  • On Wednesday, January 10th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $27.52, for a total transaction of $963,200.00.
  • On Tuesday, December 19th, Robert Berman sold 10,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $24.10, for a total transaction of $241,000.00.

Shares of BHVN stock opened at $23.62 on Friday. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $16.50 and a 52-week high of $39.51. The stock has a market capitalization of $882.43 and a price-to-earnings ratio of -4.72.

A number of hedge funds have recently modified their holdings of the business. VHCP Management II LLC grew its position in Biohaven Pharmaceutical by 3.3% in the 4th quarter. VHCP Management II LLC now owns 1,718,605 shares of the company’s stock worth $46,368,000 after purchasing an additional 54,305 shares in the last quarter. Alliancebernstein L.P. grew its position in Biohaven Pharmaceutical by 84.9% in the 4th quarter. Alliancebernstein L.P. now owns 1,597,756 shares of the company’s stock worth $43,107,000 after purchasing an additional 733,526 shares in the last quarter. BlackRock Inc. grew its position in Biohaven Pharmaceutical by 1.1% in the 4th quarter. BlackRock Inc. now owns 1,154,207 shares of the company’s stock worth $31,139,000 after purchasing an additional 12,505 shares in the last quarter. Eagle Asset Management Inc. grew its position in Biohaven Pharmaceutical by 20.4% in the 4th quarter. Eagle Asset Management Inc. now owns 1,104,999 shares of the company’s stock worth $30,207,000 after purchasing an additional 187,243 shares in the last quarter. Finally, Carillon Tower Advisers Inc. bought a new stake in Biohaven Pharmaceutical in the 4th quarter worth about $18,627,000. 61.84% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Canaccord Genuity restated a “buy” rating and issued a $34.00 target price (down previously from $39.00) on shares of Biohaven Pharmaceutical in a report on Monday, March 26th. Piper Jaffray restated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Monday, March 26th. Needham & Company LLC restated a “buy” rating on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. Finally, Barclays lowered shares of Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $30.00 to $25.00 in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $37.14.

ILLEGAL ACTIVITY NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Insider Robert Berman Sells 35,000 Shares” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-robert-berman-sells-35000-shares-of-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply